Genomes and Genes
Summary: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
Publications289 found, 100 shown here
- Colorectal cancer prevention in ulcerative colitis: a case-control studyJ Eaden
The Gastrointestinal Research Unit, Leicester General Hospital, Leicester, UK
Aliment Pharmacol Ther 14:145-53. 2000..The risk of colorectal cancer (CRC) in ulcerative colitis (UC) increases with extent and duration of disease. Identifying other risk factors would allow targeting of sub-groups at greatest risk, enabling more cost-effective surveillance...
- PPARgamma as a new therapeutic target in inflammatory bowel diseasesL Dubuquoy
INSERM U795 ex E114, Clinique des maladies de l appareil digestif et de la nutrition, Hôpital Swynghedauw, Rue A Verhaeghe, F 59037 Lille Cedex, France
Gut 55:1341-9. 2006..The aims of this review are to discuss the potential roles of PPARgamma in the physiopathology of IBD, as well as the emerging therapeutic strategies targeting this receptor...
- Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitisJeffrey B Brown
Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children s Memorial Hospital, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
Gastroenterology 138:595-605, 605.e1-3. 2010b>Mesalamine is a mainstay therapeutic agent in chronic ulcerative colitis (CUC) in which condition it reverses crypt architectural changes and reduces colitis-associated cancer (CAC)...
- The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathwayJohanna Munding
Institute of Pathology, Ruhr University Bochum, D 44789, Germany
Carcinogenesis 33:637-43. 2012..Therefore, we suggest the use of 5-ASA as a promising drug for prevention of sporadic colorectal carcinoma...
- 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populationsGeoffrey C Nguyen
Mount Sinai Hospital Centre for Inflammatory Bowel Disease, University of Toronto, Toronto, Ontario, Canada
Am J Gastroenterol 107:1298-304; quiz 1297, 1305. 2012..However, more recent population-based studies suggest no protective association. We conducted a systematic review that focused on non-referral studies to reassess the role of 5-ASA for this indication...
- Mesalamine protects against colorectal cancer in inflammatory bowel diseaseJeffrey Tang
Department of Internal Medicine, Division of Gastroenterology, Henry Ford Health System, Henry Ford Hospital, Detroit, MI 48202, USA
Dig Dis Sci 55:1696-703. 2010..Previous studies show this risk is strongly associated with dysplasia, extent of disease, duration of disease, and degree of inflammation, while chemoprevention of CRC has less support...
- Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1Vineeta Khare
Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology and Christian Doppler Laboratory for Molecular Cancer Chemoprevention, Vienna, Austria
Biochem Pharmacol 85:234-44. 2013b>Mesalamine (5-ASA) is widely used for the treatment of ulcerative colitis, a remitting condition characterized by chronic inflammation of the colon...
- Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cellsG Monteleone
Dipartimento di Medicina Interna, Cattedra di Gastroenterologia e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, University Tor Vergata of Rome, Rome, Italy
Cell Death Differ 13:202-11. 2006..Finally, we show that 5-ASA attenuates p-EGFR in ex vivo organ cultures of CRC explants. Data indicate that 5-ASA disrupts EGFR signalling by enhancing SH-PTP2 activity, and suggest a mechanism by which 5-ASA interferes with CRC growth...
- Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitisS Fiorucci
Department of Gastroenterology, University of Perugia, Perugia, Italy
Br J Pharmacol 150:996-1002. 2007b>Mesalamine is the first-line therapy for colitis, but it lacks potency and is only effective for mild-to-moderate forms of this disease...
- Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studiesFernando S Velayos
Division of Gastroenterology and UCSF Center for Colitis and Crohn s Disease, University of California, San Francisco, California 94143, USA
Am J Gastroenterol 100:1345-53. 2005..We performed a systematic review with metaanalysis of observational studies evaluating the association between 5-ASA use and colorectal cancer (CRC) or dysplasia among patients with ulcerative colitis...
- Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept studyR Corinaldesi
Department of Clinical Medicine and Center for Applied Biomedical Research, University of Bologna, Bologna, Italy
Aliment Pharmacol Ther 30:245-52. 2009..Intestinal immune infiltration contributes to symptoms in patients with irritable bowel syndrome (IBS)...
- Medications as a source of human exposure to phthalatesRuss Hauser
Department of Environmental Health, Occupational Health Program, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Environ Health Perspect 112:751-3. 2004..we report on medications as a potential source of exposure to DBP in a man who took Asacol [active ingredient mesalamine (mesalazine)] for the treatment of ulcerative colitis...
- Systematic review: adherence issues in the treatment of ulcerative colitisS V Kane
Section of Gastroenterology, Department of Medicine, The University of Chicago, Chicago, IL, USA
Aliment Pharmacol Ther 23:577-85. 2006..It is a combination of understanding patient behaviour, recognizing signs of non-adherent behaviour and utilizing management strategies to change behaviour that will improve patient outcomes...
- Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitisSunanda Kane
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Inflamm Bowel Dis 18:1026-33. 2012..to assess clinical recurrence in patients with ulcerative colitis (UC) who received maintenance treatment with MMX Multi Matrix System (MMX) mesalamine. A secondary outcome was the relationship between long-term efficacy and adherence.
- 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based studyCharles N Bernstein
University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Winnipeg, Manitoba, Canada
Am J Gastroenterol 106:731-6. 2011..We aimed to determine if use of 5-aminosalicylates (5-ASA) was associated with a reduced risk of colorectal cancer (CRC) in people with inflammatory bowel disease (IBD)...
- Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trialsStephen B Hanauer
University of Chicago Pritzker School of Medicine, Illinois, USA
Clin Gastroenterol Hepatol 2:379-88. 2004The aim of this study was to perform a meta-analysis of the efficacy results from 3 placebo-controlled multicenter clinical trials of slow-release mesalamine (Pentasa) for the acute treatment of mild to moderate Crohn's disease.
- Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cellsS Parenti
Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy
Aliment Pharmacol Ther 31:108-19. 2010..A recent observation has suggested that inhibition of beta-catenin signalling could induce these cellular effects...
- Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestationsRuni A Foster
Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32610, USA
Inflamm Bowel Dis 9:308-15. 2003Lung injury related to mesalamine (5-aminosalicylic acid) has rarely been reported in patients with inflammatory bowel diseases...
- Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeatsChristoph Campregher
Christian Doppler Laboratory for Molecular Cancer Chemoprevention, Medical University of Vienna, Vienna, Austria
Clin Cancer Res 16:1950-6. 2010..Here, we tested the effect of 5-ASA on replication fidelity in mononucleotide, dinucleotide, and tetranucleotide repeats...
- Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activityCarina L Bos
Laboratory of Experimental Oncology and Radiobiology, Department of Oncology, University of Amsterdam, The Netherlands
Carcinogenesis 27:2371-82. 2006..This study shows, using concentrations of mesalazine identical to concentrations seen in patients with inflammatory bowel disease, that mesalazine inhibits the Wnt/beta-catenin pathway via inhibition of PP2A...
- Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acidCarmine Stolfi
Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1 00133 Rome, Italy
Biochem Pharmacol 75:668-76. 2008..Taken together our data indicate that 5-ASA causes both a COX-2-dependent and -independent inhibition of CRC cell growth...
- Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitisTakayuki Yamamoto
Inflammatory Bowel Disease Centre, Yokkaichi Social Insurance Hospital, Yokkaichi, Mie, Japan
J Crohns Colitis 6:750-5. 2012..This study was to see if the introduction of GMA at an early stage reduces corticosteroid administration and steroid dependency in the long term clinical course of UC...
- Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled studyFabrizio Bossa
UU OO Gastroenterologia ed Endoscopia Digestiva, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
Am J Gastroenterol 103:2509-16. 2008..We planned a controlled study to investigate the efficacy and safety of dexamethasone 21-P (Dex 21-P) encapsulated into erythrocytes (DEE)...
- Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitisGeert D'Haens
Academic Medical Center, Amsterdam, The Netherlands
Am J Gastroenterol 107:1064-77. 2012Treatment with mesalamine to maintain endoscopic remission (mucosal healing) of ulcerative colitis (UC) has been shown to reduce the risk of relapse and is the recommended first-line maintenance therapy...
- 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancerBart Baan
Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, Amsterdam, The Netherlands
Gut 61:1708-15. 2012..In vitro data suggest that, in colorectal cancer cells, 5-ASA induces cell cycle arrest, but the molecular mechanism leading to this arrest remains to be determined...
- Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisBrian G Feagan
Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada
Cochrane Database Syst Rev 10:CD000544. 2012..This updated review includes more recent studies and evaluates the effectiveness, dose-responsiveness, and safety of 5-ASA preparations used for maintenance of remission in quiescent ulcerative colitis...
- High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trialsTessa E H Römkens
Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Inflamm Bowel Dis 18:2190-8. 2012..The aim of this study was to systematically review the medical literature in order to compare different preparations of 5-ASA for the effect on MH...
- Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phaseCarmine Stolfi
Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
Carcinogenesis 29:1258-66. 2008..Data show that mesalazine negatively regulates CDC25A protein expression, thus delaying CRC cell progression...
- Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazideP W Lowry
Division of Gastroenterology, Division of Clinical Pharmacology, Department of Pharmacology, and Section of Biostatistics, Mayo Clinic, Rochester, MN, USA
Gut 49:656-64. 2001AIM: We evaluated the effect of coadministration of sulphasalazine, mesalamine, and balsalazide on the pharmacokinetics and pharmacodynamics of azathioprine and 6-mercaptopurine...
- Systematic review: molecular chemoprevention of colorectal malignancy by mesalazineA Lyakhovich
Department of Medicine, Medical University of Vienna, Austria
Aliment Pharmacol Ther 31:202-9. 2010Mesalazine (mesalamine) (5-ASA) is considered an anti-inflammatory drug for the treatment of inflammatory bowel disease. It is well tolerated by most patients and induces mucosal healing specifically in ulcerative colitis...
- Inflammatory bowel disease: clinical aspects and established and evolving therapiesDaniel C Baumgart
Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
Lancet 369:1641-57. 2007..Finally, we summarise the practical aspects of standard therapies including dosing, precautions, and side-effects...
- Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitisMatthew Rutter
Department of Gastroenterology, University Hospital of North Tees, Stockton on Tees, Teesside, England
Gastroenterology 126:451-9. 2004..Patients with ulcerative colitis are at increased risk of colorectal cancer. It is widely believed that this is secondary to colonic inflammation. However, the severity of colonic inflammation has never been shown to be a risk factor...
- Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent diseaseReikei Matsuda
Department of Internal Medicine, Fujisawa Shounandai Hospital, Fujisawa, Kanagawa, Japan
Inflamm Bowel Dis 15:328-34. 2009..This study was to investigate the expressions of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 mRNAs in the colonic mucosa of patients with ulcerative colitis (UC) during active and quiescent UC...
- Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activityL J Egan
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Biol Chem 274:26448-53. 1999..In this report, we demonstrate that mesalamine, an anti-inflammatory aminosalicylate, dose-dependently inhibits IL-1-stimulated NF-kappaB-dependent ..
- 5-Aminosalicylic acid inhibits TGF-beta1 signalling in colorectal cancer cellsPim J Koelink
Department of Gastroenterology Hepatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
Cancer Lett 287:82-90. 2010..We conclude that 5-ASA inhibits TGF-beta1 signalling in colorectal cancer cells, and might be a potent adjuvant therapeutic drug, interfering with aberrant TGF-beta signalling in colorectal cancer...
- Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugsS G Nugent
Department of Surgery, St George's Hospital Blackshaw Road, London, UK
Gut 48:571-7. 2001..This paper reviews methods for measuring gut pH, its changes in IBD, and how these may influence current and future therapies...
- Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flaresP D R Higgins
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
Aliment Pharmacol Ther 29:247-57. 2009..Ulcerative colitis (UC) can be maintained in remission with 5-aminosalicylic acid (5-ASA) medications, but frequent non-adherence by patients who are feeling well has been associated with more frequent flares of colitis...
- Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitisWilliam J Sandborn
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Gastroenterology 138:1286-96, 1296.e1-3. 2010..This study was conducted to determine the efficacy and safety of once-daily dosing of delayed-release mesalamine (Asacol 400-mg tablets) compared with twice-daily dosing for maintaining remission in UC patients.
- 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivityEleonora Distrutti
Clinica di Gastroenterologia, Policlinico Monteluce, University of Perugia, Via Enrico Dal Pozzo, 06122 Perugia, Italy
J Pharmacol Exp Ther 319:447-58. 2006..In this study, we have investigated the role of a novel H(2)S-releasing derivative of mesalamine (5-amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester, ATB-429) in modulating nociception ..
- Nonadherence in inflammatory bowel disease: results of factor analysisPetr Cerveny
Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Prague, Czech Republic
Inflamm Bowel Dis 13:1244-9. 2007..The purpose of the study was to assess overall nonadherence to treatment among patients with Crohn's disease (CD) and ulcerative colitis (UC) in a single tertiary center...
- Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled studyP Marteau
Gastroenterology, Hopital Europeen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France
Gut 54:960-5. 2005....
- Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitisWilliam J Sandborn
Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
Gastroenterology 137:1934-43.e1-3. 2009It is not clear what induction dose of mesalamine is optimal for treating patients with mildly and moderately active ulcerative colitis (UC). This study was conducted to determine the efficacy and safety of mesalamine 4...
- Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trialStephen B Hanauer
Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
Gastroenterology 127:723-9. 2004..The aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of clinical, endoscopic, and radiographic recurrence of Crohn's disease after ..
- PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cellsMarkus Schwab
First Department of Medicine ZAFES, Johann Wolfgang Goethe University Frankfurt, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
Carcinogenesis 29:1407-14. 2008..The aim of our study was to investigate the involvement of peroxisome proliferator-activated receptor gamma (PPARgamma) in mesalazine's anticarcinogenic actions in colorectal cancer cells...
- Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomesNielsen Q Fernandez-Becker
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Drugs 68:1089-103. 2008..The development of delivery methods that allow once-daily administration represents a potential means to improve the low medication adherence rates reported in patients with ulcerative colitis...
- Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gammaChristel Rousseaux
Institut National de la Santé et de la Recherche Medicale 0114, Physiopathologie des Maladies Inflammatoires Intestinales, CHU 59037 Lille, France
J Exp Med 201:1205-15. 2005..Validation of these results was obtained with organ cultures of human colonic biopsies. These data identify PPAR-gamma as a target of 5-ASA underlying antiinflammatory effects in the colon...
- Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cellsA Reinacher-Schick
Department of Medicine, Ruhr University Bochum, Knappschaftskrankenhaus, Germany
Carcinogenesis 24:443-51. 2003..These findings may suggest a potential of mesalazine as a chemopreventive agent for colorectal cancer...
- Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitisMichael A Kamm
St Vincent s Hospital, Department of Medicine, University of Melbourne, Melbourne, Australia
Inflamm Bowel Dis 15:1-8. 2009Many patients with ulcerative colitis (UC) respond to mesalamine therapy within 8 weeks. Those not achieving remission after 8 weeks are often treated with steroids or other immunosuppressive therapies...
- 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitisMargie L Clapper
Division of Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Inflamm Bowel Dis 14:1341-7. 2008..The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia...
- 5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modesPim J Koelink
Department of Gastroenterology and Hepatology, and Leiden University Medical Center, Leiden, The Netherlands
Inflamm Bowel Dis 16:379-89. 2010....
- Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitisLinnette Yen
Global Health Economics and Outcomes Research, Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA 19087, USA
J Manag Care Pharm 18:701-12. 2012..5-aminosalicylic acid (5-ASA) is the recommended first-line treatment for active mild-to-moderate ulcerative colitis (UC) and for maintenance of UC remission. However, persistence and adherence to prescribed 5-ASAs are often suboptimal...
- Solitary rectal ulcer syndrome in children and adolescentsEmily R Perito
Department of Pediatrics, University of California, San Francisco, CA 94143 0136, USA
J Pediatr Gastroenterol Nutr 54:266-70. 2012..The aim of this study was to describe the presenting symptoms, endoscopic and histologic findings, and clinical courses of pediatric patients diagnosed with solitary rectal ulcer syndrome (SRUS)...
- Review article: Oral, modified-release mesalazine formulations--proprietary versus genericA Forbes
St Mark s Academic Institute, St Mark s Hospital, Northwick Park, Harrow, UK
Aliment Pharmacol Ther 17:1207-14. 2003..Of most importance here is that the assessment of new modified-release products is sufficiently rigorous to allow patients and physicians to be confident in their use...
- Dendrimers conjugates for colonic delivery of 5-aminosalicylic acidRuedeekorn Wiwattanapatapee
Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkla 90112, Thailand
J Control Release 88:1-9. 2003..Only a small amount of 5-ASA was found after incubation of both conjugates with the homogenate of the small intestine for 12 h. It appears that this PAMAM dendrimer can be developed for use as a carrier for colon-specific drug delivery...
- Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily doseNabeel Khan
Department of Internal Medicine, Section of Gastroenterology, Southeast Louisiana Veterans Health Care System, New Orleans, Louisiana, USA
Inflamm Bowel Dis 19:1123-9. 2013There are limited data about the long-term follow-up of patients with ulcerative colitis (UC) maintained on high versus low doses of mesalamine. We evaluated the best long-term average daily dose that would keep the disease in remission.
- The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelityChristoph Campregher
Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, and Christian Doppler Laboratory on Molecular Cancer Chemoprevention, Vienna, Austria
Inflamm Bowel Dis 16:576-82. 2010..So far neither 5-ASA's structural specificity nor its pharmacophore group have been identified. Here we compared 5-ASA with its analogs (4-ASA and 3-ASA) and its metabolite N-acetyl-5-ASA (NAc-5-ASA)...
- Mesalamine in the treatment and maintenance of remission of ulcerative colitisMaggie Ham
Center for Inflammatory Bowel Disease, BIDMC Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
Expert Rev Clin Pharmacol 5:113-23. 2012..b>Mesalamine (mesalazine) is a 5-aminosalicylic acid compound that is the first-line treatment for patients with mild-to-..
- Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up studyO A Paoluzi
Gastroenterology Unit, Department of Clinical Science, La Sapienza University, Rome, Italy
Aliment Pharmacol Ther 21:1111-9. 2005..Mesalazine as maintenance therapy in ulcerative colitis is used worldwide and has been proven to be effective. However, the optimal dosage remains to be defined...
- Novel prodrugs for the treatment of colonic diseases based on 5-aminosalicylic acid, 4'-geranyloxyferulic acid, and auraptene: biological activities and analytical assaysFrancesco Epifano
Universita degli Studi G D Annunzio, Chieti Pescara, Facolta di Farmacia, Dipartimento di Scienze del Farmaco, Via dei Vestini 31, 66100 Chieti CH, Italy
Curr Drug Deliv 9:112-21. 2012....
- The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitisBrian G Feagan
Robarts Clinical Trials, Western University, London, Ontario, Canada
Gastroenterology 145:149-157.e2. 2013..Interobserver differences in endoscopic assessments contribute to variations in rates of response to placebo in ulcerative colitis (UC) trials. We investigated whether centralized review of images could reduce these variations...
- Effects of N-acetylcysteine plus mesalamine on prostaglandin synthesis and nitric oxide generation in TNBS-induced colitis in ratsHanumantha R Ancha
Division of Gastroenterology, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
Dig Dis Sci 54:758-66. 2009..studies was to examine mechanisms by which the rectally administered combination of N-acetylcysteine (NAC) plus mesalamine (5-ASA) affects inducers of inflammation to promote mucosal healing and reduce tissue inflammation in chemically ..
- Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitisG Frieri
Cattedra di Gastroenterologia, Universita di L Aquila, L Aquila, Italy
Gut 47:410-4. 2000..The treatment of ulcerative colitis (UC) with 5-aminosalicylic acid (5-ASA) does not have the same therapeutic effect in all patients. We tested the hypothesis that the effectiveness of the drug is related to its mucosal concentration...
- Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatmentG Frieri
Gastroenterology Unit, University of L Aquila, Italy
Aliment Pharmacol Ther 13:1413-7. 1999..To measure mucosal concentrations of mesalazine in ulcerative colitis patients treated with oral mesalazine alone, compared to patients treated with both topical and oral mesalazine...
- Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot studyAshok K Tuteja
Division of Gastroenterology, University of Utah, School of Medicine, 30 N 1900 E, Salt Lake City, UT 84132, USA
Scand J Gastroenterol 47:1159-64. 2012..There is often an increase in sub-epithelial inflammatory and neuroendocrine cells on colonic mucosal biopsy. Mesalamine is an anti-inflammatory agent, effective in the treatment of inflammatory bowel disease...
- A random urine test can identify patients at risk of mesalamine non-adherence: a prospective studyAnne E Gifford
Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Am J Gastroenterol 108:249-55. 2013b>Mesalamine non-adherence is common among patients with ulcerative colitis (UC), and can be difficult to identify in practice...
- Mesalamine-associated hypersensitivity myocarditis in ulcerative colitisSundae Stelts
Ann Pharmacother 42:904-5. 2008
- Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare systemN Khan
Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA
Aliment Pharmacol Ther 36:755-64. 2012..Adherence is a major factor in determining disease activity in ulcerative colitis (UC). There are limited data on long-term nationwide adherence levels among patients with UC...
- Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitisPaul L McCormack
Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
Drugs 67:2635-42. 2007..Two of 434 MMX mesalazine recipients experienced serious adverse events that were considered treatment related (pancreatitis caused by mesalazine sensitivity)...
- Mesalamine delivery systems: do they really make much difference?Altamash I Qureshi
Department of Internal Medicine, Wayne State University, Detroit Medical Center, USA
Adv Drug Deliv Rev 57:281-302. 2005..aminosalicylates, which eliminate the sulfa-moiety, and attempt to target the topically active mesalamine to the inflamed bowel...
- Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pelletsEhab R Bendas
Department of Pharmaceutics, College of Pharmacy, Oregon State University, Corvallis, OR, USA
Drug Dev Ind Pharm 36:393-404. 2010..The basic objective of this study was to develop a novel technique that aids in compaction of coated pellets into tablets and obtain a release pattern from compressed pellets resembling the same pattern before compression...
- Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitisW Kruis
Evangelisches Krankenhaus Kalk, University of Cologne, Germany
Aliment Pharmacol Ther 33:313-22. 2011Comparative data regarding different regimens of oral mesalazine (mesalamine) for maintaining remission in ulcerative colitis are limited.
- Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteersW J Sandborn
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Aliment Pharmacol Ther 19:1089-98. 2004Existing pharmacokinetic data are insufficient to determine whether a delayed-release formulation of mesalamine (Asacol) results in greater systemic exposure to 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid ..
- Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?Peter Laszlo Lakatos
1st Department of Medicine, Semmelweis University, Koranyi S 2A, H 1083 Budapest, Hungary
Pharmacol Res 58:190-5. 2008..In this systematic review, the authors summarize the available literature on the short- and medium-term efficacy and safety of the new once daily mesalazine formulations...
- Current concept of pathophysiological understanding and natural course of ulcerative colitisMartin H Holtmann
Department of Medicine, Johannes Gutenberg University, Langenbeckstrasse 1, 55131 Mainz, Germany
Langenbecks Arch Surg 389:341-9. 2004....
- Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteersThai Hoa Joeres-Nguyen-Xuan
Evangelisches Krankenhaus Kalk, Cologne, Germany
Inflamm Bowel Dis 16:256-62. 2010b>Mesalamine and the probiotic E. coli Nissle 1917 (EcN) are both effective agents for the treatment of ulcerative colitis. A combined therapy may have more than additive efficacy. However, mesalamine may have antimicrobial effects on EcN.
- One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitisA Barney Hawthorne
Department of Medicine, University Hospital of Wales, Cardiff, UK
Inflamm Bowel Dis 18:1885-93. 2012..We aimed to investigate whether OD Asacol was as effective as three times (TDS) daily dosing, and to evaluate the role of treatment adherence...
- Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouseS R Ritland
Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Arizona 85259, USA
Clin Cancer Res 5:855-63. 1999....
- Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trialB J Rembacken
Centre for Digestive Diseases, The General Infirmary at Leeds, UK
Lancet 354:635-9. 1999..coli (Nissle 1917) was as effective as mesalazine in preventing relapse of ulcerative colitis. We also examined whether the addition of E. coli to standard medical therapy increased the chance of remission of active ulcerative colitis...
- Small intestinal release mesalamine for the treatment of refractory celiac disease type IShailaja Jamma
Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
J Clin Gastroenterol 45:30-3. 2011The goal of this study is to evaluate the safety and efficacy of Small intestinal release mesalamine (SIRM) for symptom relief in refractory celiac disease (RCD).
- Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's diseaseA Prakash
Adis International Limited, Mairangi Bay, Auckland, New Zealand
Drugs 57:383-408. 1999..4 g/day is effective in preventing postoperative recurrence of Crohn's disease. Oral delayed-release mesalazine is effective and well tolerated in sulfasalazine-intolerant patients with ulcerative colitis or Crohn's disease...
- Clinical pharmacokinetics of slow release mesalazineM De Vos
Department of Gastroenterology, Ghent University Hospital, Belgium
Clin Pharmacokinet 39:85-97. 2000..Although preliminary data support an association between mucosal concentrations of mesalazine and its clinical activity, further studies are needed to correlate the effects of this drug with its pharmacokinetic parameters...
- Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized studyHiroaki Ito
Digestive Disease Center of Excellence, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan
Inflamm Bowel Dis 16:1567-74. 2010b>Mesalamine is the first-line drug for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with UC.
- Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescentsMelvin B Heyman
Department of Pediatrics, University of California, San Francisco, California 94143 0136, USA
Inflamm Bowel Dis 16:1931-9. 2010..We conducted an open-label trial to evaluate the clinical efficacy of a mesalamine suppository (500 mg) to treat pediatric patients with mild to moderate ulcerative proctitis.
- Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysisAlexander C Ford
Leeds Gastroenterology Institute, Leeds General Infirmary, UK
Am J Gastroenterol 106:2070-7; quiz 2078. 2011..Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied this issue...
- Mesalamine for inflammatory bowel disease: recent reappraisalsGiovanni C Actis
Department of Gastro Hepatology, Ospedale Gradenigo, Torino, Italy
Inflamm Allergy Drug Targets 7:1-5. 2008Derived from the historical molecule sulfasalazine, mesalamine has remained one of the mainstays for treatment of inflammatory bowel disease in the last 50 years...
- Mesalamine derivatives in the treatment of Crohn's diseaseLaura E Harrell
Section of Gastroenterology and Nutrition, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 4076, Chicago, IL 60637, USA
Gastroenterol Clin North Am 33:303-17, ix-x. 2004..It remains to be determined whether certain high-risk groups of patients may benefit from higher doses of mesalamine induction or maintenance therapy. Mesalamine derivatives are also of benefit in the treatment of Crohn's disease...
- Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemopreventionWilliam J Sandborn
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
Rev Gastroenterol Disord 6:97-105. 2006Sulfasalazine, olsalazine, balsalazide, delayed-release mesalamine, controlled-release mesalamine, mesalamine pellets, and Multi-Matrix System mesalamine are effective first-line therapies for the treatment of mildly to moderately active ..
- A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspectiveNic Brereton
School of Health and Related Research ScHARR, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK
J Med Econ 13:148-61. 2010..To perform a cost-utility analysis of a new formulation of mesalazine (Mezavant XL, MMX mesalazine) versus an existing oral mesalazine (Asacol; mesalazine) from the UK National Health Service perspective...
- Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitisL P Piodi
U O di Gastroenterologia, Servizio di Medicina Nucleare, Milan, Italy
Scand J Gastroenterol 39:154-7. 2004..Both the efficacy of long-term intermittent therapy with low-dose 5-ASA enemas in preventing UC relapses and its economic implications were evaluated...
- The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamineWolfgang Kruis
Evangelisches Krankenhaus Kalk, University of Cologne, Cologne, Germany
Clin Gastroenterol Hepatol 1:36-43. 2003..A new pellet preparation was designed combining slow and delayed release properties. Aims of the study were to find the optimal dose and to test efficacy and safety of a new 5-aminosalicylic acid formulation...
- A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitisJohn I Mackowiak
Center for Outcomes Research, Chapel Hill, North Carolina 27517, USA
Manag Care Interface 19:39-46, 56. 2006..results from clinical trials directly comparing oral balsalazide capsules and a specific formulation of oral mesalamine. Health care costs related to UC for an oral 5-ASA failure is greater than dollar 11,500 on average in the first ..
- Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trialsMiguel Regueiro
Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
Inflamm Bowel Dis 12:979-94. 2006..The results of this review provided the content for the accompanying treatment guidelines, Clinical Guidelines for the Medical Management of Left-sided Ulcerative Colitis and Ulcerative Proctitis: Summary Statement...
- Diagnosis and treatment of ulcerative proctitisMiguel D Regueiro
Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh School of Medicine, Pennsylvania 15212, USA
J Clin Gastroenterol 38:733-40. 2004..This review highlights the pathogenesis, diagnosis, and treatment of ulcerative proctitis...
- Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteersKenji Tokui
Department of Pharmacy, Nagoya Daini Red Cross Hospital, Japan
Biol Pharm Bull 25:264-7. 2002..The present findings suggest that 5-ASA has favorable absorptive properties and can be expected to have systemic action after rectal administration of a 5-ASA enema...
- Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosingT B Vree
Institute for Anaesthesiology, Academic Hospital Nijmegen Sint Radboud, Nijmegen, The Netherlands
J Pharm Pharmacol 52:645-52. 2000..8% metabolite with I and 15.5% with II. The renal clearance of the metabolite acetylmesalazine was independent of the observed defecation patterns (300 mL min(-1), P > 0.8), stool composition, and type of absorption...
- Ulcerative proctitis: a review of pharmacotherapy and managementPeter Laszlo Lakatos
Semmelweis University, First Department of Medicine, H1083 Budapest, Koranyi S 2A, Hungary
Expert Opin Pharmacother 9:741-9. 2008..Ulcerative proctitis (UP) is a common presentation of ulcerative colitis (UC)...
- Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylatesJoel H Rubenstein
The Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA
Am J Gastroenterol 104:2222-32. 2009..Therefore, in patients prescribed 5-ASAs for maintenance of remission, annual surveillance might be overly burdensome and inefficient. We aimed to determine the ideal frequency of surveillance in patients with UC maintained on 5-ASAs...
- Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitisAntonio Tursi
Digestive Endoscopy Unit, Lorenzo Bonomo Hospital, Andria BA, Italy
Med Sci Monit 10:PI126-31. 2004..25 g/day) plus 3 g/day VLS#3 (group A) with medium-dose balsalazide alone (group B) and with mesalazine (group C) in the treatment of mild-to-moderate active ulcerative colitis...
- Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamineCarmine Stolfi
Department of Internal Medicine, University of Tor Vergata, Rome, Italy
Gastroenterology 138:221-30. 2010b>Mesalamine has been reported to protect against inflammatory bowel disease-related colorectal cancer (CRC), but several drug-related issues have limited its use in chemopreventive programs...
- Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitisAntoine Cortot
Gastroenterologie, Hopital Claude Huriez, Lille, France
Am J Gastroenterol 103:3106-14. 2008To determine in a noninferiority study whether mesalamine foam is as effective as mesalamine liquid enema for inducing clinical remission in patients with active left-sided ulcerative colitis (UC).
- Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costsWilliam N Tindall
Department of Family Medicine, Wright State University, Dayton, Ohio, USA
J Manag Care Pharm 13:S2-12; quiz S13-4. 2007..Continued disease progression and relapse of UC over time are associated with an increased risk of colorectal cancer (CRC)...
- New drug VS-110 for treating inflammatory bowel diseasesJinshyun Ruth Wu-Wong; Fiscal Year: 2013..Currently drugs for anti-inflammatory diseases in the GI tract such as mesalamine (Asacol, Lialda, Pentasa) and budesonide achieved US$2.9 billion in annual worldwide sales in 2011...
- CAT1920: A Small Molecule Therapeutic for the Treatment of IBDMICHAEL ROBERT JIROUSEK; Fiscal Year: 2010..The proposal presented in this Phase I SBIR grant application will establish the mechanism of action of CAT1920 and its utility as a novel, safe and efficacious therapeutic for the treatment of IBD. ..
- Predicting Response to Standardized Pediatric Colitis Therapy: The PROTECT StudyMi Ok Kim; Fiscal Year: 2011..for a clinical trial of early IM use in pediatric UC patients unlikely to achieve steroid-free remission with mesalamine alone, 2) discovering fundamental new knowledge regarding the role of common genetic and environmental factors ..
- Chemoprevention of Colitis-Associated Neoplasia by 5-ASAMargie L Clapper; Fiscal Year: 2012..Findings from the proposed mouse studies could lead to the use of 5-ASA for cancer prevention and significantly impact the establishment of future guidelines for the clinical management of patients with inflammatory bowel disease. ..
- Predicting Response to Standardized Pediatric Colitis Therapy: PROTECT StudyJEFFREY SAMUEL HYAMS; Fiscal Year: 2013..Longstanding disease carries a high risk of colon cancer. Ideally, UC is adequately controlled with mesalamine, a 5-aminosalicylate with a favorable benefit: risk profile...
- Crossover Study on Human Exposure to Phthalates and Male FertilityRuss B Hauser; Fiscal Year: 2013..S. population. The source of DBP exposure was Asacol (mesalamine, with enteric coating containing DBP) used to treat inflammatory bowel disease (IBD)...
- Targeting Oxidative Stress in Chronic Beryllium DiseaseLisa A Maier; Fiscal Year: 2013..The studies will mechanistically target these changes with a novel therapeutic approach using 5 aminosalicylic acid in CBD subjects. ..
- HIV, Gut Mucosal Turnover and Inflammation, and the Risk of Colorectal NeoplasiaMa Somsouk; Fiscal Year: 2013..are associated with the presence of neoplasia in both HIV+ and HIV- individuals, and (3) to determine whether mesalamine decreases gut epithelial turnover and mucosal inflammation among HIV+ individuals in the context of an ongoing ..
- 5ASA REGULATION OF MNSOD IN INTESTINAL CELLSJohn Valentine; Fiscal Year: 2002..The peak onset of IBD is between 15 and 25 years of age and the majority of patients with IBD are under age 40. Mesalamine (5-ASA) is the active ingredient in sulfasalazine and is one of the major therapies use to treat active disease ..
- CYTOKINE MODULATION OF INFLAMMATORY BOWEL DISEASEGARY VARILEK; Fiscal Year: 2000..E (vit E) and glutathione (GSH)-enhancing agents, and by anti-inflammatory agents, such as glucocorticoids, mesalamine, and cyclosporine...
- BIOADHESIVE POLYMERS FOR TREATMENT OF COLON DISEASEJindrich Kopecek; Fiscal Year: 2000..The results of proposed studies will provide a new therapeutic method for the treatment of ulcerative colitis. Moreover, they will be of importance for the development of other colon-specific drug delivery systems. ..
- Multi-site Trial of Azathioprine Dosing in Crohn DiseaseStephen Hanauer; Fiscal Year: 2003..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
- Multi-site Trial of Azathioprine Dosing in Crohn DiseaseStephen Hanauer; Fiscal Year: 2004..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
- Randomized Trial of Rosiglitazone for Ulcerative ColitisJames Lewis; Fiscal Year: 2005..If our hypothesis is correct, this study will serve to establish that ligands for PPARg possess biological activity necessary to modulate the inflammatory response in the intact human colon. ..
- Trefoil Factors in GI Cancer BiologySteven H Itzkowitz; Fiscal Year: 2010..The results of these studies could provide insights into novel treatment strategies for gastrointestinal malignancies. ..
- Maternal Phthalate Exposure and Infertility, Fetal LossRuss Hauser; Fiscal Year: 2007..Since occupational and environmental exposure to phthalates is widespread, detecting even small adverse effects will have large public health significance. ..
- STUDY OF REG RECEPTOR-LIGAND BIOLOGY IN GI MUCOSABrian Dieckgraefe; Fiscal Year: 2008..These studies will also provide new insight into the role of Reg IV antagonists and lay the groundwork for development of therapeutic reagents active in gastrointestinal adenocarcinomas. ..
- Pilot study on the safety and efficacy of ciprofloxacin for prophylactic preventiHans Herfarth; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- NF-kB in the intestinal radiation responseLaurence Egan; Fiscal Year: 2005..These results will provide mechanistic insight into an important medically relevant problem, amd will point the way towards novel therapies to prevent radiation injury to the intestines. ..
- Adenosine in trauma and sepsisGyorgy Hasko; Fiscal Year: 2007..abstract_text> ..
- Association of PPAR gamma ligands & colonic neoplasiaJames Lewis; Fiscal Year: 2006..Our results will allow us to translate the existing in vitro and in vivo observations to the intact human colon and could lead to further chemoprevention strategies. ..
- TFF3 GENE EXPRESSION IN METASTATIC COLON CANCERSteven Itzkowitz; Fiscal Year: 2001..The use of the TFF3 gene to drive expression of suicide genes offers a novel approach which should result in more targetted, safer gene therapy for metastatic colon cancer. ..
- Pathologic Markers of Genetic Damage and Disease in IBDMelvin Heyman; Fiscal Year: 2005..abstract_text> ..
- Analysis of the Chemopreventive Activity of FGN 1MARGIE CLAPPER; Fiscal Year: 2004....
- OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory BoBRUCE SANDS; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- IKK Beta In Intestinal InflammationLaurence Egan; Fiscal Year: 2005..abstract_text> ..
- Clinical Approaches to Ileal Pouch DysfunctionBo Shen; Fiscal Year: 2005..The AIMS of study are to 1) investigate visceral hypersensitivity using barostat examination of the pouch; 2) conduct a randomized, placebo-controlled clinical trial evaluating the use of amitriptyline in IPS. ..
- Maternal Pesticide Exposure and Pregnancy OutcomesRuss Hauser; Fiscal Year: 2009..Since the etiology of infertility and early pregnancy loss remains largely unexplained, the identification of potential environmental risk factors will have large public health significance. ..
- IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASEBRUCE SANDS; Fiscal Year: 2004..The principal investigator seeks to become an independent clinical investigator by completing the didactic and scientific portions of this proposal. ..
- Assessment of Infant Outcomes After in Utero Exposure to Antiretroviral TherapySonia Hernandez diaz; Fiscal Year: 2010..We propose to evaluate the risk of congenital malformations and other adverse pregnancy outcomes following antenatal exposure to ART in a prospective cohort of pregnant women. ..
- IMURAN Dose Ranging Study in Crohn's DiseaseBRUCE SANDS; Fiscal Year: 2005..Abstract Not Provided ..